Member Info for Globalcrossings

In:) GLA

....

GLA

Jubilant Energy N.V. Drilling Update Share On Facebook Print Alert TIDMJUB RNS Number : 9623K Jubilant Energy N.V. 05 August 2013 5 August 2013 Jubilant Energy NV ("Jubilant" or "the Company") Spudding of the Sixth Well of Phase-III-Extension Development Drilling Campaign in the Oil Producing Kharsang Field Jubilant is pleased to announce that KPL-3E-5, the sixth and last well of the Phase-III-Extension development drilling campaign in the oil producing Kharsang Field, was spudded on 2 August 2013. KPL-3E-5, located in the northern part of the field, is being drilled as an infill development well between KSG#22 and KSG#42, with the D-00 reservoir sand layer as primary objective, and the G-00 sand layers as secondary objectives. The well is planned to deviate by approximately 318.5 metres to the west from the existing plinth of the well KSG#42, and will be drilled to a target depth of approximately 1,015 metres Measured Depth("MD"), and 950 metres True Vertical Depth ("TVD"). The fifth development well of the current campaign, KSG#69 (previously referred to as KPL-3E-1), which was spudded on 24 June 2013, was successfully drilled to a revised target depth of 1,563.6 metres MD, and 1,358.4 metres TVD. Formation evaluation is in progress for this well, using the results of wire-line logs, drill cuttings and formation pressure data from the Reservoir Dynamic Tester. The consortium will be testing the hydrocarbon bearing sands and expects to put the deepest oil-bearing sand in production soon. The KSG#69 well will be tested with a smaller capacity work-over rig, which will be mobilized to the site shortly. A further release will follow regarding the actual test results. GeoEnpro Petroleum Ltd., a joint venture between GeoPetrol and Jubilant Enpro (a member of the wider Jubilant Bhartia Group), is the operator of the Kharsang Field. Jubilant holds a 25 percent interest in the block through its subsidiary, Jubilant Energy (Kharsang) Pvt. Ltd. The other members of the consortium are Oil India Ltd. and GeoPetrol.

RNS Number : 9525K Alkane Energy PLC 05 August 2013 5 August 2013 Alkane Energy plc ("Alkane" or "the Group") Acquisition of Licence Alkane Energy plc (AIM: ALK), the independent gas to power producer, is pleased to announce the completion of the acquisition from GP Energy Limited ("GP") of a part licence interest in United Kingdom Onshore Licence AL010 for coal mine methane exploitation (the "Acquisition") which was announced on 24 July 2013. The Acquisition was subject to the approval of the Secretary of State for Energy and Climate Change of the transfer of the part licence interest. This approval has now been received. For more information please contact: Alkane Energy plc Neil O'Brien, Chief Executive Officer Steve Goalby, Finance Director 01623 827927 Altium Capital Limited Adrian Reed

After a whole year preparation work on channel sales, we are confident that FY2014 will see reasonable growth in channel sales. In the meantime, the group has also actively looked to control costs and tighten its cost control systems. We hope that these initiatives will create a firm foundation for the year ahead. Our revenue and profit before tax were slightly higher than the previous year. We continue to focus our business in the banking, police, and government security agency sector and continue to provide high quality software, products and services to our customers. During the year, BlueStar was awarded ten copyrights in respect of its new software solutions for advanced networking platforms and intelligent management functions. In November 2012, BlueStar was named in the China Public Security Magazine as one of the "Ten most influential DVR brands in China 2012." We will continue to streamline our management practices and improve operational efficiency aiming at being even more responsive to our customers' needs. We are sincerely grateful to our customers and stakeholders for their continued long term trust and support. We would particularly like to thank our workforce for their commitment and dedication to customer service. Liu Xiaochuan Chairman, Non-Executive Director Financial Review For the year ended 31 March 2013, revenue was up on the previous year by 5% to RMB 186 million (2012: RMB 176 million) and profit after tax up by 60% to RMB 3.3 million (2012: RMB 2.0 million). Gross profit for the year ended 31 March 2013 was RMB 86 million (2012: RMB 90 million) and average gross profit margins for the period decreased from 51% in 2012 to 46%. The declined gross profit margin is mainly driven by rising costs which we were unable to pass through to our customers. The principal increase in input costs is expected to be short term as it was a result of devastating floods in Thailand during 2011, which have adversely impacted the technology sector across the world as it has led to higher hard disk costs. The new channel sales of equipment and IPC also contributed to lower profit margin. However it will improve the Company's cash flow in the future. The overall operating expense has reduced by 8% as the Company has been undertaking a series of cost reductions including reducing the executive directors' salaries by 30% and the non-executive directors' salaries by 50%. BlueStar maintained its expenditure on research and development and, as planned, during the year, the Company's investment in R&D amounted to RMB 18 million (2012: RMB 19 million) of which RMB 11 million was capitalised (2012: RMB 10 million). During the year, BlueStar has invested RMB 1.5 million (2012: RMB 1.0 million) mainly in conjunction with our cooperation with the Kaiyuan Company ("Kaiyuan"), a partner that has been appointed by the Beijing Municipal Public Security Bureau as its sole security service provider for

RNS Number : 6120K BlueStar SecuTech, Inc. 31 July 2013 31 July 2013 BlueStar SecuTech Inc Final Results for the Year Ended 31 March 2013 BlueStar SecuTech Inc. ("BlueStar", "the Company" or "the Group"), the AIM quoted (AIM: BSST) leading provider of digital video surveillance solutions in China, is pleased to announce its final audited results for the 12 months ended 31 March 2013. Highlights for the year -- Revenues up 5% to RMB 186 million (31 March 2012: RMB 176 million) -- Gross profit down 4% to RMB 86 million (31 March 2012: RMB 90 million) -- Gross margin down 5% to 46% (31 March 2012: 51%) -- Fully diluted earnings per share 4.47 fen (31 March 2012: 2.79 fen) (100 fen = 1 RMB) -- Profit before tax up 51% to RMB 7 million (31 March 2012: RMB 5 million) -- Cash position of RMB 27 million at year end (31 March 2012: RMB 51 million) -- No dividend will be declared in respect of financial year ended 31 March 2013 Commenting on the results, Xiao Gang, Chief Executive of BlueStar said: "Despite the revenue and net profit of the Group in this financial year being better than the same period last year, the result did not meet management's expectation. The main reason is due to the decline in gross profit caused by rising costs, as well as an increase in interest payments on the Company's bank debts. Management of the group's receivables continues to be a challenge and working capital management is aided by the continued commitment of our banks. "Looking at our current contracts and order book, the Company believes the business for the next financial year will benefit from an investment in expanding the group's channel sales business. The Company will keep on working hard to expand its market share, to tighten the cost control and to address working capital management." Enquiries:- BlueStar SecuTech, Antonia Ping CFO & Company +86 (0) 10 8225 Inc. Secretary 5855 ---------------------- ---------------------------- ---------------- Westhouse Securities +44 (0) 20 7601 Limited Richard Baty 6100 ---------------------- ---------------------------- ---------------- Chairman's Statement The financial year 2013 has been another challenging year for our business, although we continue to win new contracts and new clients. Throughout the year, the Company has intended to increase its revenue in two ways: one is to continue to win more banking clients; the other is to grow the group's channel sales business. During the last year, the channel sales team has increased from 18 to 54 members and the team has stepped up its marketing activities with Exhibition activities and trade fairs conducted in around 30 cities to actively expand the recognition of BlueStar's brand.

She is making her way upwards:)

About to tick-up... Again:)

RNS Number : 5779K EPE Special Opportunities PLC 31 July 2013 EPE Special Opportunities Plc Interest Payment on Convertible Loan Notes (CLN) EPE Special Opportunities Plc is pleased to announce that pursuant to RNS Number 4489K made on 15 July 2011, the Company has today paid interest due to Convertible Loan Note holders of GBP0.0375 per CLN with a record date of 12 July 2013. Enquiries: EPIC Private Equity LLP James Henderson Tel: +44 (0) 20 7269 8862 IOMA Fund and Investment Management Limited Philip Scales Tel: +44 (0) 1624 681 250 Numis Securities Ltd Tel: +44 (0) 20 7260 1000 Nominated Adviser: Stuart Skinner / Hugh Jonathan Corporate Broker: Charles Farquhar This information is provided by R

She's ticking upwards:)!

Aaahh... Why not..? Only a few quid, but enough to put a smile on my face if she has long legs:) GLA

Getting Tighter:)

The market cap is a bit on the high-side for my typical swing trade... Hmmm... Should or not..? Anybody taking a dip into SKP???:)

Morning Sir... I think I'll take a whack at this...:)

RNS Number : 5732K Skyepharma PLC 31 July 2013 flutiform(R) recommended for approval in Japan LONDON, UK, 31 July, 2013 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, announces that the Pharmaceutical Affairs and Food Sanitation Council's Second Committee on Drugs, of the Japanese Ministry of Health, Labour and Welfare ("MHLW"), has recommended approval of flutiform(R) for bronchial asthma treatment in Japan. flutiform(R) is licensed to Kyorin Pharmaceutical Co, Ltd. ("Kyorin") for Japan. A milestone of several million U.S. Dollars is payable to Skyepharma on approval of flutiform(R) in Japan. Skyepharma will also receive high-mid single digit royalties on net sales. The new drug application for flutiform(R) will now be considered by the MHLW's regulatory committee (Bunka-Kai) for the official administrative marketing authorisation. In parallel, the MHLW is also considering pricing for the National Health Insurance drug price list, which must be agreed prior to any launch. flutiform(R) combines for the first time in Japan the fast acting LABA (Long-Acting Beta Agonist), formoterol, and the ICS (Inhaled Corticosteroid), fluticasone. Peter Grant, Chief Executive Officer of Skyepharma, commented: "The recommendation for approval of flutiform in Japan follows encouraging feedback from Skyepharma's partners on progress made in the initial launch markets in Europe. We look forward to the continued roll-out of flutiform in other countries, providing asthma patients with a new and effective treatment option." -Ends- For further information please contact: Skyepharma PLC

TIDMIND RNS Number : 3710K IndigoVision Group PLC 29 July 2013 IndigoVision Group PLC ("IndigoVision" or the "Company") Pre close trading update Sales for the year to 31st July 2013 are expected to be around GBP32m, ahead of the previous year and in line with market estimates. Following extensive improvements to the product range in the last two years, intelligent camera sales are expected to be up over 30% year on year, more than offsetting reductions in traditional encoder sales. Intelligent cameras are expected to account for half of group revenues in the year to 31st July 2013. As anticipated at the interim stage, gross margins improved during the second half, but remain lower than last year overall reflecting the changing product mix of sales towards intelligent cameras. Overheads have continued to rise as planned, with further investment in the sales and distribution network and in product development. Operating profits for the year to 31st July 2013 are expected to be below earlier expectations and market estimates. Pre tax profits for the year to 31st July 2013 are expected to be approximately GBP2m (prior year GBP2.3m). Marcus Kneen, chief executive, said: "We have made progress towards our goal of repositioning IndigoVision to achieve market rates of sales growth, and the rapid growth of intelligent camera sales in the current year demonstrates what IndigoVision is capable of. During the current year we have again broadened the core product range significantly and increased the sales and pre-sales headcount by one third. The benefit of this investment in future growth has begun to show through in intelligent camera sales growth, but the transition has impacted the operating result for the year." The results for the year to 31st July 2013 are expected to be announced on 26 September 2013. For further information please contact: IndigoVision Group plc Marcus Kneen (CEO) Holly McComb (CFO)

I'm in and let's see if she can grow some legs. GLA

Did you catch the RNS just released for VEC?

TIDMVEC RNS Number : 2623K Vectura Group plc 26 July 2013 Ultibro(R) Breezhaler(R) (QVA149), a first in class, once-daily, dual bronchodilator, gains positive CHMP opinion for the treatment of COPD -- QVA149 (indacaterol/glycopyrronium) is the first once-daily, fixed-dose combination of long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) bronchodilators to gain positive opinion from the Committee for Medicinal Products for Human Use (CHMP) -- Pivotal Phase III IGNITE study data showed QVA149 significantly improved lung function and patient-reported outcomes, including breathlessness and rescue medication use, compared to current standard of care(1) -- QVA149 demonstrated significantly reduced rates of COPD exacerbations and improved health-related quality of life compared to open-label tiotropium 18 mcg and glycopyrronium 50 mcg(2,3) Chippenham, 26 July 2013 - Vectura Group plc ("Vectura"; LSE: VEC) is pleased to note the information released today by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro(R) Breezhaler(R) (indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Ultibro Breezhaler was developed under the name QVA149. QVA149 is an investigational, fixed-dose combination of two bronchodilators, indacaterol, a long-acting beta2-adrenergic agonist (LABA) and glycopyrronium, a long-acting muscarinic antagonist (LAMA). Dr Chris Blackwell, Chief Executive of Vectura, commented: "The CHMP's opinion supports QVA149 as a treatment option for COPD and represents a very important step towards the approval of QVA149 in Europe. The positive results returned from the Phase III IGNITE program give us confidence that QVA149 could be the first LAMA/LABA combination product to provide benefit to patients with COPD, a growing, multi-billion dollar market." QVA149 significantly improved the rate of all exacerbations compared to open-label (OL) tiotropium 18 mcg, glycopyrronium 50 mcg and was comparable to salmeterol/fluticasone (SFC) 50 mcg/500 mcg(3) . The rate of moderate or severe exacerbations was significantly lower compared to glycopyrronium 50 mcg and was numerically lower compared to OL tiotropium 18 mcg(2,3) . In clinical studies undertaken by Novartis, QVA149 demonstrated an acceptable safety profile with no meaningful differences in the incidence of adverse and serious adverse events between the treatment groups (placebo, indacaterol 150 mcg, glycopyrronium 50 mcg, OL tiotropium 18 mcg, SFC 50 mcg/500 mcg)(2,4,5) . The European Commission generally follows the recommendations of the CHMP and normally grants a marketing authorization within three months of